Jaipur, April 1, 2025: Lupin Human Welfare & Research Foundation (Lupin Foundation), the CSR arm of global pharma major, Lupin Limited (Lupin), in collaboration with the State Health Department, organized a two-day state-level workshop. Senior medical officers from district hospitals across Rajasthan participated in the workshop, held from 25 – 26 March 2025, in Jaipur.

This workshop is part of the “Lives” Program from Lupin Foundation, aimed to strengthen healthcare systems and address the rising prevalence of Non-Communicable Diseases (NCDs). Over 60 senior medical officers were trained on updated guidelines* for accurate diagnosis and treatment of hypertension and coronary artery disease, COPD and asthma. The sessions were led by distinguished medical experts, Dr. Naresh Munot (Cardiologist) and Dr. Aparna Birajdar (Pulmonologist).

The workshop was inaugurated by Dr. Sunil Singh, Joint Director (Non-Communicable Diseases), Health Department, Government of Rajasthan, and Ms. Tushara Shankar, Head – CSR, Lupin. Other notable attendees included Mr. Arun Vashishta (State Program Officer, Health Department, Government of Rajasthan), Dr. Nachiket Sule (Head – Healthcare, Lupin Foundation), and Mr. Ravi Dadhich (District Program Manager, Healthcare, Lupin Foundation). Their presence highlighted the critical importance of this initiative in advancing public health within the state.

Sunil Singh, Joint Director of Non-Communicable Diseases at Rajasthan’s Health Department said, “The increase in non-communicable diseases challenges our public health system. This workshop is vital for updating our medical officers with the latest skills to tackle these diseases. By collaborating with Lupin Foundation, we aim to provide high-quality healthcare and better health outcomes for the people of Rajasthan.”

Speaking on the occasion, Tushara Shankar, Head – CSR, Lupin said, “This initiative aligns with Lupin’s vision of providing the best to the communities we serve. It is a testament to our commitment to strengthening healthcare systems and building a resilient society. By equipping our medical officers with latest knowledge and skills**, we are striving to enable better health for the people of Rajasthan.”

* For Asthma: GINA guidelines (Global Initiative for Asthma or Genetic Information Nondiscrimination Act)
For COPD: GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease)
For Hypertension: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
For Ischemic Heart disease: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

** ECG and spirometry related skills

About Lupin Foundation
Lupin Human Welfare & Research Foundation (Lupin Foundation) is the social responsibility arm of Lupin limited, which has been working to positively impact rural landscapes since 1988. During its three-decade history, the foundation has touched over 5000 villages in 23 districts across nine states. The organization has been working to address all aspects of development for underprivileged communities in four thematic areas, namely Economic, Social, Infrastructure Development, and Natural Resource Management. It undertakes economic development activities in the fields of agriculture, animal husbandry, women empowerment, and rural industries. The social anchors include health and education, while infrastructure development and natural resource development have been the key drivers of growth in backward regions where it operates. LHWRF has adopted a new strategic approach to working on Lives (Healthcare) and Livelihoods.

For further information please contact:
Ravi Dadhich
lhwrfcommunications@lupin.com

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin